logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

ImmunoGen Reports Recent Progress and 2Q 2023 Financial Results. In Other News, Anna Berkenblit, MD, Senior VP and CMO Stepping Down from Her Position

ImmunoGen in the News WALTHAM, Mass.--(BUSINESS WIRE) --Jul. 31, 2023-- ImmunoGen ( IMGN ) , a leader in the expanding field of antibody-drug conjugates ( ADCs ) for the treatment of cancer, today reviewed recent progress in the business and...

Read More

July 31, 2023

0

Positive News for TCR2 Therapeutics - The U.S. FDA Granted Orphan Drug Designation to Gavo-Cel for Cholangiocarcinoma

TCR2 Therapeutics TCR2 Therapeutics ( TCRR )  is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from cancer. TCR2’s proprietary T cell receptor ( TCR ) Fusion Construct T cells (TRuC®-T cells)...

Read More

September 2, 2021

0

Vertex Stock Soars Pre-Market Announcing Positive Results from Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

Vertex Pharmaceuticals in the NEWS Today, December 13, 2023, Vertex  Pharmaceuticals ( VRTX ) announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with painful diabetic peripheral neuropathy ( DPN ). Treatment...

Read More

December 13, 2023

0

Reminders About CymaBay Therapeutics and Jazz Pharmaceuticals Conference Calls Today at 4.30 PM

CymaBay Therapeutics and Jazz Pharmaceuticals Conference Call Info CymaBay Therapeutics: Hosting a Conference Call and Live Audio Website at 4.30 PM  TODAY CymaBay Therapeutics, Inc. ( CBAY ) - a clinical-stage biopharmaceutical company developing therapies for liver and other chronic...

Read More

August 10, 2023

0

Editas Medicine and Vertex Pharmaceuticals: Non-Exclusive License Agreement in Cas9 Gene Editing Technology  

Editas Medicine and Vertex Pharmaceuticals in the NEWA Today December 13, 2023, Editas Medicine ( EDIT ) announced that it entered into an agreement with Vertex Pharmaceuticals ( VRTX ) . The Terms of the Agreement: Vertex will obtain a...

Read More

December 13, 2023

0

Interesting, Good News for Impel NeuroPharma and Migraine Sufferers

Impel NeuroPharma FDA Approval for TRUDHESA The U.S. Food and Drug Administration ( FDA ) approved Impel NeuroPharma ( IMPL ) product TRUDHESA (dihydroergotamine mesylate ( DHE )), previously known as INP104, a nasal spray for the treatment of acute...

Read More

September 3, 2021

0

Merck & Invivyd in Today's December 18, 2023 News

Merck & Invivyd in the NEWS Our post today comprises a premarket drug rejection. An important new approval for Merck's ( MRK ) Keytruda product, and exciting promising trial results for the firm Invivyd, Inc. ( IVVD ) viral protection....

Read More

December 18, 2023

0

Why IVERIC bio Stock Rallied Today

IVERIC bio Stock Rally IVERIC bio ( ISEE ) stock rallied in early, premarket trading today as Stifel Nicolaus initiated a buy rating and a price target of $22. In premarket the stock was trading over $13.37, UP over $4...

Read More

September 10, 2021

0

Regenxbio and AbbVie: A Good Reason for RGNX to Soar Today

Regenxbio and AbbVie in the NEWS Regenxbio ( RGNX ) stock soared today. The Company, along with AbbVie ( ABBV ), announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related...

Read More

September 13, 2021

0

Regeneron Pharmaceuticals EYLEA HD Approved by FDA for Wet Age-related Macular Degeneration, Diabetic Macular Edema and Diabetic Retinopathy

Regeneron Pharmaceuticals EYLEA HD Approved by the FDA Regeneron Pharmaceuticals ( REGN ) announced that the U.S. FDA has approved EYLEA HD ( aflibercept ) Injection 8 mg for the treatment of patients with wet age-related macular degeneration ( wAMD ),...

Read More

August 21, 2023

0

  • Previous
  • 1
  • 2
  • ...
  • 146
  • 147
  • 148
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy